10 Apr. 2019
DUKE MARGOLIS CENTER FOR HEALTH POLICY, WASHINGTON DC
Marc Gitzinger, representing the BEAM Alliance, was one of the invited speakers at the Duke Margolis Center: Understanding the Development Challenges...
10 Apr. 2019
CARB-X WELCOMES UK GOVERNMENT AND BILL & MELINDA GATES FOUNDATION AS NEW PARTNERS
UK GOVERNMENT AND BILL & MELINDA GATES FOUNDATION JOIN CARB-XPARTNERSHIP IN FIGHT AGAINST SUPERBUGS Millions earmarked to boost research into n...
11 Apr. 2019
INVESTORS KEEN TO PUT MONEY INTO AMR SMES - BIOCOM CONFERENCE REPORT
nvestments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life S...
11 Apr. 2019
SME FINANCING AND MARKET ACCESS HURDLES IN THE FOCUS OF AMR CONFERENCE
200 experts followed invitation of BEAM Alliance and BIOCOM AG to build a discussion platform for most important AMR related challenges 50+ speakers...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
